Tetramethylpyrazine-porphyrin derivative and anti-tumor application thereof
By designing ligustrazine-porphyrin derivatives, combining the synergistic effects of PDT and chemotherapy drugs, the problem of photodynamic therapy in damage to normal tissues has been solved, and the selective inhibition of tumor cells and the improvement of anti-cancer effects has been achieved, and the effect of expanding the Application range of anti-cancer compounds.
Patent Information
- Application Number
- CN202411441203.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-16
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-10-16
AI Technical Summary
Although the existing photodynamic therapy (PDT) is selective in anti-tumor treatment, it has a great damage to normal tissues, and the mechanism of synergistic effects of chemotherapy drugs and photosensitizers has not been fully understood, which limits its clinical application.
A ligustrazine-porphyrin derivative was designed to reduce the anti-cancer effect by synergistically acting with PDT and chemotherapy drugs. damage.
The selective inhibition of tumor cells has been achieved, the range of anti-cancer compounds has been broadened, the side effects on normal cells have been reduced, and the anti-tumor activity of compounds has been enhanced, especially under the synergistic effect of phototherapy and chemotherapy, it has significantly improved the anti-cancer effect. .
Smart Images

Figure CN119080787A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of pharmaceutical chemistry, and in particular to a chuanxiongzine-porphyrin derivative and its anti-tumor application. Background Art
[0002] Photodynamic therapy (PDT), as an emerging non-invasive therapy mediated by reactive oxygen species (ROS), has received increasing attention in recent years. It has been applied to the treatment of cancers such as laryngeal cancer, skin cancer, and breast cancer, and has achieved certain therapeutic effects. Since PDT can selectively act on tumor tissues and hardly affect the functions of normal tissue cells, it has the advantages of small toxic side effects and is particularly suitable for people who are intolerant of traditional cancer treatments such as chemotherapy and radiotherapy. The reactive oxygen species generated during PDT (including hydroxyl radicals generated by type I and singlet oxygen generated by type II) can oxidize biological macromolecules (proteins, nucleic acids, and lipids) in the system. After these biological macromolecules that are essential for life are oxidized, they interfere with the normal life activities of cells, thereby causing apoptosis and necrosis of tumor cells. To give full play to the therapeutic effect of PDT, it is first necessary to select a suitable photosensitizer.
[0003] With the development of PDT, the preparation of photosensitizers, especially porphyrin photosensitizers, has made remarkable progress. Most photosensitizers used for cancer treatment have a macrocyclic skeleton based on porphyrin. The main advantages of porphyrin compounds in photodynamic research include: 1) stability of aromatic compounds; 2) effective absorption of visible light; 3) high yield of reactive oxygen; 4) easy functionalization and structural diversity; 5) long triplet lifetime and low dark toxicity. Photofri, the first photosensitizer approved by the US FDA, is a classic porphyrin structure drug.
[0004] Li et al. (Chinese Chemical Letters, 2007, 18(11): 1331-1334) designed and synthesized a new potential targeted anticancer drug based on porphyrin and 5-fluorouracil, and evaluated the in vitro anticancer activity of human liver cancer cell SMCC-7721 by MTT method. Preliminary results showed that the anticancer activity of the coupled products was more than twice that of 5-fluorouracil. Porphyrin had no killing effect on tumor cells under light-free conditions, indicating that the coupled products actually improved the targeting of 5-fluorouracil to tumor tissues, thereby enhancing the anticancer activity. S. Weimin et al. (Bioorg Med Chem, 2008, 16(10): 5665-5671) coupled 5-fluorouric acid / Boc-L-phenylalanine with aminoporphyrin to synthesize a series of porphyrin compounds containing 5-fluorouracil / L-phenylalanine. The results of in vitro anticancer activity studies show that the introduction of 5-fluorouracil and L-phenylalanine can significantly increase the phototoxicity of porphyrins. The high selectivity of porphyrin compounds for tumor tissues has broadened the prospects for the research of anticancer drug-linked porphyrin compounds.
[0005] Ligustrazine (tetramethylpyrazine, TMP) is the main active ingredient extracted from a plant called Ligustrazine. It has a long history and wide application in traditional Chinese medicine. TMP has many pharmacological effects, including vasodilation, anti-platelet aggregation, and blood circulation regulation. It is often used to treat headaches, migraines, angina pectoris, strokes and other diseases. With the in-depth study of Ligustrazine, it may have the potential to inhibit the proliferation and metastasis of cancer cells. A series of in vitro studies have shown that Ligustrazine can effectively inhibit the proliferation of various cancer cell lines, including but not limited to breast cancer, liver cancer and lung cancer. Further research on the mechanism of action of Ligustrazine found that it may exert its anti-cancer effect through multiple pathways such as regulating the cell cycle, promoting cell apoptosis and inhibiting angiogenesis. Specifically, Ligustrazine may affect the growth and metastasis ability of cancer cells, thereby inhibiting the development of tumors. These research results provide an important theoretical basis for further exploring the potential application of Ligustrazine in cancer treatment, and also provide new ideas and directions for its clinical application and drug development. However, although the in vitro experimental results showed the anticancer potential of ligustrazine, its effectiveness and safety in clinical application still need to be further studied and verified. Therefore, further clinical trials and pharmacological studies will help to comprehensively evaluate the potential value of ligustrazine as an anticancer drug and its clinical application prospects.
[0006] The ligustrazine-porphyrin derivatives designed in the present invention exert excellent anti-cancer efficacy under the synergistic effect of PDT and chemotherapy drugs, providing important scientific basis and technical support for the application expansion of porphyrin and its derivatives in the field of biomedicine. Summary of the invention
[0007] The technical problem to be solved by the present invention is to provide a ligustrazine-porphyrin derivative, which has excellent anti-cancer efficacy under the synergistic effect of PDT and chemotherapy drugs, while causing less damage to normal tissues and achieving selective inhibition of tumor cells.
[0008] The first aspect of the present invention is to provide a compound represented by Formula I or Formula II and a pharmaceutically acceptable salt thereof, which has the following structure:
[0009]
[0010] Wherein, n is selected from an integer of 1-8;
[0011] R is independently selected from H, halogen, hydroxy, nitro, CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 2-10 heteroaryl;
[0012] R' is selected from H, halogen, hydroxy, nitro, CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl;
[0013] M is selected from Zn, Ni, and Mn.
[0014] Preferably, n is selected from 1, 2, 3, 4 or 5.
[0015] Preferably, R is independently selected from H, halogen, hydroxy, nitro, CN, C 1-6 Alkyl; More preferably, R is each independently selected from H, or Cl;
[0016] Preferably, R' is selected from H, halogen, hydroxy, nitro, CN, C 1-6 Alkyl; More preferably, R is selected from H;
[0017] Preferably, M is selected from Zn.
[0018] Another aspect of the present invention provides a method for preparing a compound of formula I, and the synthetic route is as follows:
[0019]
[0020] Wherein, n, R, and R' are as defined above.
[0021] The specific reaction steps are as follows:
[0022] In an organic solvent, a base, a catalyst and porphyrin 1 are added, heated and stirred, and a ligustrazine derivative 2 is added to the reaction system until the reaction is completed. After post-treatment, a porphyrin-ligustrazine derivative of formula I is obtained.
[0023] Preferably, the molar ratio of the porphyrin derivative 1 to the ligandrazine derivative 2 is: 1:(1-1.5), preferably 1:1-1.2, more preferably 1:1.2
[0024] The base is selected from potassium hydroxide, triethylamine or potassium carbonate, more preferably potassium carbonate.
[0025] The catalyst is selected from one or both of potassium iodide and sodium iodide.
[0026] Another aspect of the present invention provides a method for preparing a compound of formula II, and the synthetic route is as follows:
[0027]
[0028] wherein n, R, R' and M are as defined above.
[0029] The specific reaction steps are as follows:
[0030] The compound of formula I is dissolved in an organic solvent, and M metal salt is added, and the reaction is refluxed and monitored by TLC until the reaction is complete. After post-treatment, the ligandrazine-porphyrin derivative of formula II is obtained.
[0031] Preferably, the molar ratio of the compound of formula I to the metal salt of M is 1:3-7, preferably 1:5.
[0032] Another aspect of the present invention provides a pharmaceutical composition comprising a compound represented by Formula I or Formula II or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier and excipient.
[0033] Another aspect of the present invention relates to the use of a compound of formula I or formula II and a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the same in the preparation of an anticancer drug;
[0034] Preferably, gastric cancer, non-small lung cancer cells, prostate cancer, bladder cancer, colon cancer cells, breast cancer; in particular, the cancer is caused by human gastric cancer cells HGC-27, human non-small lung cancer cells A549, human prostate cancer cells DU145, human bladder cancer cells TCCSUP, human colon cancer cells HCT-116 or human breast cancer cells MDA-MB-231.
[0035] Compared with the prior art, the present invention has the following beneficial effects:
[0036] (1) The present invention provides a new class of chuanxiongzine-porphyrin derivatives with anticancer activity, which broadens the scope of existing anticancer compounds and can be used as lead compounds for further optimization;
[0037] (2) The compound of the present invention uses porphyrin molecules as carriers and utilizes its tumor tissue aggregation effect to target tumor cells, thereby reducing the side effects of killing normal cells.
[0038] (3) The chuanxiongzine-porphyrin derivatives of the present invention can achieve the synergistic effect of phototherapy and chemotherapy. In addition, inserting metal Zn into porphyrin can also enhance the anti-tumor activity of the compound. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Figure 1 Effect of compound 8d on the migration of DU145 cells. DETAILED DESCRIPTION
[0040] The following examples are provided to illustrate the present invention in detail. The following examples are provided to better illustrate the present invention and are not intended to limit the scope of the present invention. The materials, reagents, etc. used in the following examples, unless otherwise specified, can be obtained from commercial sources.
[0041] Example 1 Synthesis of Porphyrins 4 and 5
[0042]
[0043] Pyrrole is easy to deteriorate during storage. When it is used, a re-evaporation device needs to be set up. The temperature is maintained at 140℃, and the condensation reflux is carried out in the dark. The initial turbid part is discarded, and the clear and transparent newly evaporated pyrrole is collected. 4.8g of p-hydroxybenzaldehyde and 6.1mL of benzaldehyde are added to a 250mL three-necked flask. 120mL of propionic acid is used as a solvent to completely dissolve the raw materials. After reflux at 135℃ for 0.5h, 11mL of pyrrole is diluted to 22mL with propionic acid and slowly dripped along the wall of the tube through a constant pressure dropping funnel. The dripping rate is strictly controlled to be about 0.5h. The dripping is continued for 1h. After the reaction is completed, it is cooled to room temperature; 60mL of anhydrous ethanol is added to the reaction solution, and it is placed at 4℃ overnight, filtered, and dried to obtain a black purple solid crude product. Dichloromethane: n-hexane is used as a developing solvent in a ratio of 3:1. The silica gel chromatography column is purified, the product band is collected, and the solvent is removed under reduced pressure to obtain a blue purple solid porphyrin 4.
[0044] Porphyrin 4: Yield: 7%, 1HNMR (500MHz, Chloroform-d) 8.89–8.83 (m, 8H), 8.22 (d, J = 6.7Hz, 6H), 8.11–8.06 (m, 2H), 7.75-7.70 (m, 9H), 7.26 (d, J = 7.8Hz, 2H), -2.76 (s, 2H) ppm.
[0045]
[0046] In a 250mL three-necked flask, 4.8g of p-hydroxybenzaldehyde and 16.8g of p-chlorobenzaldehyde were added, and 120mL of propionic acid was used as a solvent to completely dissolve the raw materials. After reflux at 135°C for 0.5h, 11mL of pyrrole was diluted to 22mL with propionic acid and slowly dripped along the tube wall through a constant pressure dropping funnel. The dripping rate was strictly controlled for about 0.5h, and the dripping was continued for 1h. After the reaction was completed, it was cooled to room temperature; 60mL of anhydrous ethanol was added to the reaction solution, and it was placed at 4°C overnight, filtered, and dried to obtain a dark purple solid crude product. Dichloromethane was used as a developing solvent, and the product band was collected by silica gel chromatography column purification, and the solvent was removed under reduced pressure to obtain a blue purple solid porphyrin 5.
[0047] Porphyrin 5: Yield: 8% 1HNMR (500MHz, Chloroform-d) δ9.05 (d, J = 4.7Hz, 2H), 8.95–8.92 (m, 6H), 8.15 (d, J =7.8Hz, 6H), 8.01 (d, J = 8.1Hz, 2H), 7.74 (d, J = 8.0Hz, 6H), 7.26 (d, J = 6.0Hz, 2H), -2.82 (s, 2H) ppm.
[0048] Example 2 Synthesis of Ligustrazine Derivatives 3a-3e
[0049]
[0050] Prepare a 50mL round-bottom flask, accurately weigh 0.1g (0.6mmol) of ligustrazine formic acid, 0.414g (3mmmol) of anhydrous potassium carbonate, and 48.5μL (1.5mmol) of triethylamine, and fully dissolve them in DMF (8-10mL); after stirring at room temperature / 60°C for 0.5h, accurately pipette 87μL (0.72mmol) of 1,6-dibromohexane / 96μL (0.72mmol) of 1,5-dibromopentane / 79.4μL (0.72mmol) of 1,4-dibromobutane / 126μL (0.72mmol) of 1,3-dibromopropane / 63μL (0.72mmol) of 1,2-dibromoethane into the reaction system, and monitor the reaction progress by TCL; after the reaction is completed, use dichloromethane as an extractant, extract the reaction solution 3 times, collect dichloromethane, and wash with pure water 3-5 times to remove DMF as much as possible. Anhydrous Na2SO4 was used to remove the water in dichloromethane, and the crude products of 3a-3e were obtained as pale yellow viscous liquids. Methanol: dichloromethane = 20:1 was used as the developing solvent, and the crude products were purified by silica gel chromatography. The organic solution was collected and evaporated under reduced pressure to obtain pale yellow viscous liquid compounds 3a-3e.
[0051] 3a: 1HNMR (500MHz, DMSO-d6) δ4.29 (t, J = 6.6 Hz, 2H), 3.53 (t, J = 6.7 Hz, 2H), 2.59 (s, 3H) ,2.51(s,3H),2.47(s,3H),1.83-1.78(m,2H),1.73-1.67(m,2H),1.45-1.39(m,4H)ppm.
[0052] 3b: 1HNMR (500MHz, DMSO-d6) δ4.3 (t, J = 6.8 Hz, 2H), 3.52 (t, J = 6.2 Hz, 2H), 2.5 9(s,3H),2.51(s,3H),2.48(s,3H),1.91–1.85(m,4H),1.68–1.61(m,2H)ppm.
[0053] 3c: 1HNMR (500MHz, DMSO-d6) δ4.31 (t, J = 6.4 Hz, 2H), 3.51 (t, J = 5.9 Hz, 2H), 2.57 (s, 3H), 2.52 (s, 3H), 2.49 (s, 3H), 1.84–1.79 (m, 4H) ppm.
[0054] 3d: 1HNMR (500MHz, DMSO-d6) δ4.29 (t, J = 6.5 Hz, 2H), 3.52 (t, J = 6.1 Hz, 2H), 2.57 (s, 3H), 2.51 (s, 3H), 2.47 (s, 3H), 1.96-1.91 (m, 2H) ppm.
[0055] 3e: 1HNMR (500MHz, DMSO-d6) δ4.29 (t, J = 6.6 Hz, 2H), 3.52 (t, J = 6.7 Hz, 2H), 2.58 (s, 3H), 2.52 (s, 3H), 2.47 (s, 3H) ppm.
[0056] Example 3 Synthesis of ligandrazine-porphyrin of formula I
[0057]
[0058] 0.54mmol of 3a / 3b / 3c / 3d / 3e (the intermediate is in liquid state, so it is difficult to calculate the yield, and the conversion rate is calculated to be 90%) in a 50mL round-bottom flask was diluted with 15mL DMF, and 0.55mmol of porphyrin 4 / porphyrin 5, 0.414g of anhydrous potassium carbonate, and 0.1g of potassium iodide were added. The reaction was carried out at 60°C for 12h. The reaction time was adjusted by TLC monitoring. After the reaction was completed, dichloromethane was used as an extractant to extract the reaction solution three times, and dichloromethane was collected and washed with pure water for 3-5 times to remove DMF as much as possible. Anhydrous Na2SO4 was used to remove the moisture of dichloromethane, and vacuum rotary evaporation was performed to obtain a purple solid crude product. The crude product was purified using a silica gel chromatography column, and dichloromethane: acetone = 50:1 was used as the developing solvent. The third purple band was collected to obtain derivatives 6a-6e and 7a-7e. The synthesized 6a-6e and 7a-7e were treated with dichloromethane as solvent, 0.11 g of zinc acetate was added to introduce metallic zinc, and the reaction was continued at a slight boiling reflux for 2 h to terminate the reaction. The unreacted zinc acetate was washed with an appropriate amount of pure water, and the organic phase was dehydrated with anhydrous Na2SO4. The reaction was dried under reduced pressure to obtain bright purple solids 8a-8e and 9a-9e.
[0059] 6a: Yield: 78%. 1 HNMR(500MHz,Chloroform-d)δ8.89–8.84(m,8H),8.21(d,J=6.9Hz,6H),8.12–8.08( m,2H),7.75(m,9H),7.28(d,J=8.0Hz,2H),4.48(t,J=6.8Hz,2H),4.24(t,J=6.3Hz,2H ),2.77(s,3H),2.57(s,3H),2.55(s,3H),2.05–1.99(m,2H),1.97–1.93(m,2H),1.76– 1.70(m,2H),1.68–1.62(m,2H),-2.77(s,2H)ppm.FTMS: C58H50N6O3: 878.3944; [M+H] + :879.4008.
[0060] 6b: Yield: 82%. 1HNMR (500 MHz, Chloroform-d) δ 8.89–8.84 (m, 8H), 8.24–8.20 (m, 6H), 8.11 (d, J=8.0 Hz, 2H), 7.79–7.73 (m, 9H), 7.28 (d, J=8.5 Hz,, 2H), 4.53 (t, J=6.8 Hz, 2H), 4.28 (t, J=6.2 Hz, 2H), 2.80 (s, 3H), 2.60 (s, 3H), 2.57 (s, 3H), 2.10–2.00 (m, 4H), 1.84–1.78 (m, 2H), -2.77 (s, 2H) ppm. FTMS: C57H48N6O3: 864.3788; [M+H] + : 865.3850.
[0061] 6c: Yield: 85%. 1 HNMR (500 MHz, Chloroform-d) δ 9.00 (d, J=4.8 Hz, 2H), 8.94–8.91 (m, 6H), 8.14 (d, J=7.9 Hz, 6H), 8.10 (d, J=8.0 Hz, 2H), 7.74 (d, J=7.8 Hz, 6H), 7.28 (d, J=8.2 Hz, 2H), 4.61 (t, J=6.3 Hz, 2H), 4.35 (t, J=5.8 Hz, 2H), 2.80 (s, 3H), 2.60 (s, 3H), 2.58 (s, 3H), 2.22–2.13 (m, 4H) ppm. FTMS: C56H46N6O3: 850.3631; [M+H] + : 851.3704.
[0062] 6d: Yield: 81%, 1 HNMR (500 MHz, Chloroform-d) δ 8.87–8.84 (m, 8H), 8.22 (d, J=6.4 Hz, 5H), 8.12 (d, J=8.1 Hz, 2H), 7.80–7.71 (m, 9H), 7.29 (d, J=8.1 Hz, 2H), 4.78 (t, J=6.4 Hz, 2H), 4.43 (t, J=6.0 Hz, 2H), 2.82 (s, 3H), 2.61 (s, 3H), 2.58 (s, 3H), 2.61–2.48 (m, 2H), -2.77 (s, 2H) ppm. FTMS: C55H44N6O3: 836.3475; [M+H] + : 837.3538.
[0063] 6e: Yield: 82%, 1HNMR (500 MHz, Chloroform-d) δ 8.85 (d, J=10.8 Hz, 8H), 8.22 (d, J=7.6 Hz, 6H), 8.13 (d, J=7.9 Hz, 1H), 7.78–7.73 (m, 9H), 7.33 (d, J=8.4 Hz, 2H), 5.03–4.90 (m, 2H), 4.71–4.58 (m, 2H), 2.89–2.85 (m, 3H), 2.64–2.58 (m, 6H), -2.77 (s, 2H) ppm. FTMS: C54H42N6O3: 822.3318; [M+H] + : 823.3391.
[0064] 7a: Yield: 84%, 1 HNMR (500 MHz, Chloroform-d) δ 8.91 (d, J=4.7 Hz, 2H), 8.82 (d, J=8.7 Hz, 6H), 8.14 (d, J=8.2 Hz, 6H), 8.10 (d, J=8.2 Hz, 2H), 7.74 (d, J=8.0 Hz, 6H), 7.28 (d, J=8.2 Hz, 2H), 4.50 (t, J=6.9 Hz, 2H), 4.25 (t, J=6.3 Hz, 2H), 2.79 (s, 3H), 2.59 (s, 3H), 2.56 (s, 3H), 2.03–1.98 (m, 2H), 1.97–1.91 (m, 2H), 1.74–1.68 (m, 2H), 1.65–1.61 (m, 2H), -2.82 (s, 2H) ppm. FTMS: C58H47Cl3N6O3: 982.2746; [M+H] + : 983.2822.
[0065] 7b: Yield: 80%, 1 HNMR (500 MHz, Chloroform-d) δ 8.91 (d, J=4.8 Hz, 2H), 8.83 (d, J=4.8 Hz, 6H), 8.16–8.12 (m, 6H), 8.10 (d, J=8.2 Hz, 2H), 7.74 (d, J=8.0 Hz, 6H), 7.27 (d, J=8.2 Hz, 2H), 4.54 (t, J=6.8 Hz, 2H), 4.28 (t, J=6.2 Hz, 2H), 2.80 (s, 3H), 2.60 (s, 3H), 2.58 (s, 3H), 2.10–2.00 (m, 4H), 1.84–1.78 (m, 2H), -2.83 (s, 2H) ppm. FTMS: C57H45Cl3N6O3: 966.2619; [M+H] +: 967.2691.
[0066] 7c: Yield: 85%, 1 HNMR(500MHz, Chloroform-d) δ8.90(d, J = 4.8Hz, 2H), 8.83–8.81(m, 6H), 8.14(d, J = 8.3Hz, 6H), 8.10(d, J = 8.2Hz, 2H), 7.75(d, J = 8.2Hz, 6H), 7.28(d, J = 8.3Hz, 2H), 4.62(t, J = 6.3Hz, 2H), 4.34(t, J = 5.8Hz, 2H), 2.81(s, 3H), 2.60(s, 3H), 2.57(s, 3H), 2.23–2.13(m, 4H), -2.83(s, 2H) ppm. FTMS: C56H43Cl3N6O3: 952.2642; [M+H] + : 953.2535.
[0067] 7d: Yield: 85%, 1 HNMR(500MHz, Chloroform-d) δ8.89(d, J = 4.7Hz, 2H), 8.83–8.81(m, 6H), 8.14(d, J = 7.9Hz, 6H), 8.10(d, J = 8.1Hz, 2H), 7.75(d, J = 8.0Hz, 6H), 7.30(d, J = 8.2Hz, 2H), 4.78(t, J = 6.4Hz, 2H), 4.44(t, J = 6.0Hz, 2H), 2.82(s, 3H), 2.61(s, 3H), 2.59(s, 3H), 2.53–2.48(m, 2H), -2.84(s, 2H) ppm. FTMS: C55H41Cl3N6O3: 938.2306; [M+H] + : 939.2378.
[0068] 7e: Yield: 84%, 1 HNMR(500MHz, Chloroform-d) δ8.89–8.80(m, 8H), 8.16–8.11(q, J = 9.6, 9.0Hz, 8H), 7.74(d, J = 7.8Hz, 6H), 7.33(d, J = 8.4Hz, 2H), 4.96(s, 2H), 4.65(s, 2H), 2.88(d, J = 10.2Hz, 3H), 2.61(d, J = 11.1Hz, 6H), -2.84(s, 2H) ppm. FTMS: C54H39Cl3N6O3: 954.2249; [M+H] + : 925.2210.
[0069] 8a: Yield: 90%, 1 HNMR (500 MHz, Chloroform-d) δ 9.01–8.90 (m, 8H), 8.26–8.20 (m, 6H), 8.11 (d, J = 8.1 Hz, 2H), 7.81–7.71 (m, 9H), 7.25 (d, J = 5.0 Hz, 2H), 4.47 (t, J = 6.8 Hz, 2H), 4.25 (t, J = 6.3 Hz, 2H), 2.74 (s, 3H), 2.58 (s, 3H), 2.55 (s, 3H), 2.04–1.98 (m, 2H), 1.97–1.94 (m, 2H), 1.75–1.71 (m, 2H), 1.67–1.62 (m, 2H) ppm. FTMS: C58H48N6O3Zn: 940.31048; [M+H] + : 941.3115.
[0070] 8b: Yield: 91%, 1 HNMR (500 MHz, Chloroform-d) δ 8.99 (d, J = 4.6 Hz, 2H), 8.94 (d, J = 3.0 Hz, 6H), 8.24–8.21 (m, 6H), 8.11 (d, J = 8.3 Hz, 2H), 7.79–7.73 (m, 9H), 7.27 d, J = 5.0 Hz, 2H), 4.52 (t, J = 6.8 Hz, 2H), 4.29 (t, J = 6.2 Hz, 2H), 2.78 (s, 3H), 2.60 (s, 3H), 2.57 (s, 3H), 2.10–2.00 (m, 4H), 1.84–1.78 (m, 2H) ppm. FTMS: C57H46N6O3Zn: 926.2953; [M+H] + : 927.2963.
[0071] 8c: Yield: 92%, 1 HNMR (500 MHz, Chloroform-d) δ 9.00 (d, J = 4.8 Hz, 2H), 8.94-8.91 (m, 6H), 8.14 (d, J = 7.9 Hz, 6H), 8.10 (d, J = 8.0 Hz, 2H), 7.74 (d, J = 7.8 Hz, 6H), 7.28 (d, J = 8.2 Hz, 2H), 4.61 (t, J = 6.3 Hz, 2H), 4.35 (t, J = 5.8 Hz, 2H), 2.80 (s, 3H), 2.60 (s, 3H), 2.58 (s, 3H), 2.22–2.13 (m, 4H) ppm. FTMS: C56H44N6O3Zn: 912.2838; [M+H]+ : 913.2818.
[0072] 8d: Yield: 91%, 1 HNMR(500 MHz, Chloroform-d) δ 8.98–8.94 (m, 8H), 8.22 (d, J = 6.9 Hz, 6H), 8.12 (d, J = 7.9 Hz, 2H), 7.79–7.73 (m, 9H), 7.28 (d, J = 8.6 Hz, 2H), 4.76 (t, J = 6.4 Hz, 2H), 4.43 (t, J = 5.9 Hz, 2H), 2.80 (s, 3H), 2.61 (s, 3H), 2.58 (s, 3H), 2.52–2.48 (m, 2H) ppm. FTMS: C55H42N6O3Zn: 898.2610; [M+H] + : 899.2662.
[0073] 8e: Yield: 90%, 1 HNMR(500 MHz, Chloroform-d) δ 8.96–8.93 (m, 8H), 8.23–8.20 (m, 6H), 8.13 (d, J = 8.5 Hz, 2H), 7.78–7.78 (m, 9H), 7.32 (d, J = 8.4 Hz, 2H), 4.95 (t, J = 4.8 Hz, 2H), 4.65 (t, J = 4.8 Hz, 2H), 2.87 (s, 3H), 2.62 (s, 3H), 2.60 (s, 3H) ppm. FTMS: C54H40N6O3Zn: 884.2504; [M+H] + : 885.2511.
[0074] 9a: Yield: 92%, 1 HNMR(500 MHz, Chloroform-d) δ 9.01 (d, J = 4.6 Hz, 2H), 8.94–8.90 (m, 6H), 8.14 (d, J = 7.9 Hz, 6H), 8.09 (d, J = 8.1 Hz, 2H), 7.74 (d, J = 8.0 Hz, 6H), 7.28 (d, J = 5.0 Hz, 2H), 4.48 (t, J = 6.8 Hz, 2H), 4.27 (t, J = 6.4 Hz, 2H), 2.76 (s, 3H), 2.59 (s, 3H), 2.56 (s, 3H), 2.02 (p, J = 6.7 Hz, 2H), 1.95 (p, J = 7.1 Hz, 2H), 1.76–1.70 (m, 2H), 1.67–1.28 (m, 2H) ppm. FTMS: C58H45Cl3N6O3: 1042.1910; [M+H] +: 1043.1958.
[0075] 9b: Yield: 92%, 1 HNMR(500MHz, Chloroform-d) δ9.01(d, J = 4.7Hz, 2H), 8.95–8.90(m, 6H), 8.14(d, J = 8.0Hz, 6H), 8.10(d, J = 8.4Hz, 2H), 7.74(d, J = 8.0Hz, 6H), 7.27(d, J = 4.1Hz, 2H), 4.51(t, J = 6.8Hz, 2H), 4.28(t, J = 6.2Hz, 2H), 2.77(s, 3H), 2.60(s, 3H), 2.57(s, 3H), 2.10–1.99(m, 4H), 1.84–1.79(m, 2H) ppm. FTMS: C57H43Cl3N6O3: 1028.1801; [M+H] + : 1029.1805.
[0076] 9c: Yield: 90%, 1 HNMR(500MHz, Chloroform-d) δ8.98(d, J = 4.6Hz, 2H), 8.94(d, J = 3.0Hz, 6H), 8.22(d, J = 6.9Hz, 6H), 8.11(d, J = 8.1Hz, 2H), 7.79–7.73(m, 9H), 7.28(d, J = 8.3Hz, 2H), 4.61(t, J = 6.3Hz, 2H), 4.35(t, J = 5.7Hz, 2H), 2.81(s, 3H), 2.60(s, 3H), 2.57(s, 3H), 2.23–2.13(m, 4H) ppm. FTMS: C56H41Cl3N6O3: 1014.1617; [M+H] + : 1015.1650.
[0077] 9d: Yield: 91%, 1HNMR(500MHz,Chloroform-d)δ8.99(d,J=4.7Hz,2H),8.93–8.91(m,6H),8.14 (d,J=7.9Hz,6H),8.10(d,J=8.4Hz,2H),7.74(d,J=8.1Hz,2H),7.28(d,J=9.1 Hz,2H),4.74(t,J=6.3Hz,2H),4.42(t,J=5.7Hz,2H),2.78(s,3H),2.60(s,3H ),2.58(s,3H),2.51–2.46(m,2H)ppm.FTMS: C55H39Cl3N6O3: 1000.1441; [M+H] + :1001.1497.
[0078] 9e: Yield: 91%, 1 HNMR(500MHz,Chloroform-d)δ8.98(d,J=4.7Hz,2H),8.94-8.91(m,6H),8.13(dd,J=6.8,4.8Hz,8H),7.74(d,J=8.1Hz,6H),7.33(d,J=8. 4Hz, 2H), 4.95 (t, J = 4.8Hz, 2H), 4.65 (t, J = 4.8Hz, 2H), 2.86 (s, 3H), 2.62 (s, 3H), 2.60 (s, 3H) ppm. FTMS: C54H37Cl3N6O3: 986.1301; [M+H] + :987.1342.
[0079] Example 4 Scratch Anti-Migration Study
[0080] DU145 cells were inoculated in a 6-well plate, and the cell density reached 90%. A 20 μL pipette tip was used to gently scrape a scratch along a straight line on the surface of the 6-well plate. The width and depth of the scratch were ensured to be consistent by adjusting the angle and pressure of the pipette tip. The free cells and cell debris generated by the scratch area were washed away with PBS buffer, making the scratch area clearly visible. The serum-free medium containing 8d was prepared to be lower than the IC value of DU145 cells. 50Three concentrations, namely 4μM, 8μM and 16μM, were added to a 6-well plate, and a negative control group was set up (serum-free medium eliminates the interference caused by proliferation under serum conditions). An inverted microscope was used to observe and take photos to record the initial state of the scratch. The time was marked as 0h. The 6-well plate was returned to the constant temperature incubator for continued culture. At the 12th hour, a plate was taken out for illumination for 10 minutes; after 24 hours, the scratch area was photographed again to record the degree of cell migration. Using image processing software, the area of the scratch area was calculated, and the migration rate = (initial scratch area-final migration area) / initial scratch area × 100%.
[0081] The test results are attached. Figure 1 , by the attached Figure 1 It can be seen that after 24 hours, the cell migration rate was significantly different from that of the control group, and the effect of 8d on the migration of DU145 cells was concentration-dependent. After light treatment at 12 hours, the anti-migration ability at a concentration of 16μM was greater than that of the group without light treatment; while the anti-migration ability after light treatment at concentrations of 4μM and 8μM was slightly less than that of the group without light treatment. The reason for the difference may be due to the influence of ROS levels. Low levels of ROS have a promoting effect on cell migration, while high levels have an inhibitory effect; Chuanxiongzine compounds themselves have an anti-cell migration effect. At low concentrations of 8d compounds, the ROS generated by light is less and the anti-migration ability is weakened by the antagonistic effect of Chuanxiongzine. At high concentrations, the high level of ROS and Chuanxiongzine form a synergistic anti-migration effect. In summary, the 8d compound has a good anti-migration effect. The anti-migration rate of DU145 cells under light conditions reached 41%, and the anti-migration rate of the non-light group reached 32%.
[0082] Example 5 MTT colorimetric assay for detecting anti-tumor cell activity in vitro
[0083] The inhibitory activity of the target compound and the control compound on different cells was determined by the MTT method. A blank control group, a negative control group, a positive control group, and an experimental group were set up, in which DMSO was used as the negative control group, 5-FU and Ce6 were used as the positive control groups, and the raw material ligustrazine (TMP), porphyrin compounds (4, 5) and target compounds 6a-9e were used as the experimental groups. Six replicate wells were set for the blank control group and the negative control group, and three replicate wells were set for the positive control group and the experimental group.
[0084] Table 1 In vitro anti-proliferation activity of ligustrazine-porphyrin derivatives against HGC-27 and A549
[0085]
[0086] Table 2 In vitro anti-proliferation activity of ligustrazine-porphyrin derivatives against DU145 and TCCSUP
[0087]
[0088] Table 3 In vitro anti-proliferation activity of ligustrazine-porphyrin derivatives against HCT-116 and MDA-MB-231
[0089]
[0090] Table 4 In vitro anti-proliferation activity of ligustrazine-porphyrin derivatives
[0091]
[0092] As can be seen from Table 1, Table 2, Table 3 and Table 4, the ligustrazine-porphyrin derivatives of the present invention exhibit different degrees of inhibitory effects on various cell lines under light / dark conditions. After light treatment, the ligustrazine-porphyrin derivative series compounds exhibited inhibitory effects on all cell lines. After the cells take in the compounds, laser irradiation is used to produce PDT effect that can effectively damage cells by producing ROS; without light treatment, due to the anti-tumor effect of ligustrazine, it also has an anti-proliferative effect.
Claims
1. A chuanxiongzine-porphyrin derivative and a pharmaceutically acceptable salt thereof, which has a structure shown in Formula I or Formula II: in, n is an integer selected from 1 to 8; R is independently selected from H, halogen, hydroxy, nitro, CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 2-10 heteroaryl; R' is selected from H, halogen, hydroxy, nitro, CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl; M is selected from Zn, Ni, and Mn.
2. The ligandrazine-porphyrin derivative and its pharmaceutically acceptable salt according to claim 1, characterized in that: n is selected from 1, 2, 3, 4 or 5. R is selected from H, halogen, hydroxy, nitro, CN, C1-6 alkyl; preferably, R is selected from H or Cl; R' is selected from H, halogen, hydroxy, nitro, CN, C1-6 alkyl; preferably, R is selected from H; M is selected from Zn.
3. A method for preparing the compound of formula I as claimed in claim 1, wherein the reaction scheme is as follows: in, n, R, and R' are as defined in claim 1. The specific reaction steps are as follows: add a base and porphyrin 1 to an organic solvent, heat and stir, add the ligandrazine derivative 2 to the reaction system until the reaction is completed, and obtain the ligandrazine-porphyrin derivative of formula I through post-treatment.
4. The preparation method according to claim 3, characterized in that: The molar ratio of the porphyrin derivative 1 to the ligandrazine derivative 2 is: 1:(1-1.5); the base is selected from potassium hydroxide, triethylamine or potassium carbonate, more preferably potassium carbonate.
5. A method for preparing the compound of formula II as claimed in claim 1, wherein the reaction scheme is as follows: in, n, R, R' and M are as defined in claim 1; The specific reaction steps are as follows: dissolving the compound of formula I in an organic solvent, adding M metal salt, reflux reaction, monitoring by TLC until the reaction is complete, and obtaining the ligandrazine-porphyrin derivative of formula II through post-treatment.
6. The preparation method according to claim 5, characterized in that: The molar ratio of the compound of formula I to the metal salt of M is 1:3-7, preferably 1:
5.
7. A pharmaceutical composition comprising the chuanxiongzine-porphyrin derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 2, and a pharmaceutically acceptable carrier.
8. Use of the chuanxiongzine-porphyrin derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 2 or the pharmaceutical composition according to claim 7 in the preparation of a drug for treating cancer.
9. The method of claim 8, wherein the cancer is selected from gastric cancer, non-small lung cancer cells, prostate cancer, bladder cancer, colon cancer cells, and breast cancer.
10. The use according to claim 8, wherein the cancer is caused by human gastric cancer cells HGC-27, human non-small lung cancer cells A549, human prostate cancer cells DU145, human bladder cancer cells TCCSUP, human colon cancer cells HCT-116 or human breast cancer cells MDA-MB-231.
Citation Information
Patent Citations
Preparation method of porphyrin photosensitizer and anticarcinogen diad
CN102617610A
Porphyrin-chrysin compounds and anti-tumor activity thereof
CN109912607A
Ultraviolet-responsive metalloporphyrin complex, preparation method thereof and preparation method of polycarbonate
CN112062783A
Porphyrin-eugenol derivative as well as preparation method and application thereof
CN116554182A
